Zhang YY, et al. - The inefficiency of the International Prognostic Index in initial risk stratification for patients with R-CHOP [the addition of rituximab to a CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like regimen]-treated diffuse large B-cell lymphoma (DLBCL) has led researchers to investigate patients (n = 85) in China with DLBCL in order to estimate the predictive values of PET (positron emission tomography)/CT (computed tomography) quantitative parameters and three prognostic models including baseline and interim parameters for three-year progression-free survival (PFS). Using a receiver operating characteristics curve, Kaplan-Meier analysis, and log-rank test, they analyzed PET/CT parameters, ie, the baseline and interim values of standardized uptake value (SUV_max), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG), and their rates of change. Findings revealed the independent prognostic value of the baseline variables, ie, TMTV₀, TLG₀ and dichotomized National Comprehensive Cancer Network International Prognostic Index, and the interim variables TMTV₁ and %ΔSUV_max, for PFS. Nineteen (82.6%) of the relapse or progression events were detected by the group with TLG₀ > 1036.61 g and %ΔSUV_max < 86.02% in the prognostic model 2 (TLG₀ + %ΔSUV_max), which displayed the best screening ability among three models including baseline and interim PET/CT parameters.